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RNA interfering (RNAi) using short interfering RNA (siRNA) is becoming a promising
approach for cancer gene therapy. However, owing to the lack of safe and efficient
carriers, the application of RNAi for clinical use is still very limited. In this study, we have
developed cadmium sulphoselenide/Zinc sulfide quantum dots (CdSSe/ZnSQDs)-based
nanocarriers for in vitro gene delivery. These CdSSe/ZnS QDs are functionalized with
polyethyleneimine (PEI) to form stable nanoplex (QD-PEI) and subsequently they are
used for siRNA loading which specially targets human telomerase reverse transcriptase
(TERT). High gene transfection efficiency (>80%) was achieved on two glioblastoma
cell lines, U87 and U251. The gene expression level (49.99 ± 10.23% for U87,
43.28 ± 9.66% for U251) and protein expression level (51.58 ± 7.88% for U87,
50.69± 7.59% for U251) of TERT is observed to decrease substantially after transfecting
the tumor cells for 48 h. More importantly, the silencing of TERT gene expression
significantly suppressed the proliferation of glioblastoma cells. No obvious cytotoxicity
from these QD-PEI nanoplexes were observed over at 10 times of the transfected doses.
Based on these results, we envision that QDs engineered here can be used as a safe
and efficient gene nanocarrier for siRNA delivery and a promising tool for future cancer
gene therapy applications.
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INTRODUCTION
Glioblastoma is the most common and aggressive primary central nervous system (CNS) tumor.
The prognosis of glioblastoma remains very poor to date and highly lethal with the average
survival time of patients with glioblastoma is estimated to be 1 year (Redmond and Mehta, 2015).
Although, standard therapeutic approaches have been used to combat this disease, current therapies
are still insufficient in treating the glioblastoma patients (Adamson et al., 2009). Glioblastoma is
highly infiltrative and relatively resistant to conventional therapeutic approaches. Therefore, the
development of new, novel and effective therapeutic strategy is of utmost importance to cure this
deadly disease.
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RNA interference (RNAi) is a promising technique with great
opportunity to battle with cancer (Mansoori et al., 2014). The
discovery of RNAi has generated profound therapeutic promises
for gene therapy of cancer using small interfering RNA (siRNA)
(Seyhan, 2011). The process of RNAi is complex and initiated
by double-stranded siRNA with a typical length of around 21
base pairs. The siRNA is sequenced to the target gene and able
to arouse a sequence-specific gene silencing in post-transcription
level. In the past years, RNAi-based cancer gene therapy has been
extensively explored (Maduri, 2015; Gan et al., 2016). The success
of RNAi therapeutic approach depends on two important factors,
namely, efficient therapeutic targets and the delivery efficiency.
Telomerase is an attractive target for cancer gene therapy due
to its high prevalence in almost all of the tumor cells (Tian et al.,
2010). The important function of telomerase is to prolong the life
span of cells by maintaining the telomere length (Lu et al., 2013).
Activation of telomerase is the critical step in oncogenesis and
cellular immortality. Human telomerase reverse transcriptase
(TERT) is the catalytic protein subunit of telomerase and it is very
critical for the activity of telomerase in tumor cells (Osterhage
and Friedman, 2009). The dysfunction of TERT will prevent the
long-term survival of tumor cells and promote cell apoptosis and
death. Based on these known facts, considerable new strategies
including RNAi have been explored to target the TERT gene for
cancer gene therapy (Xie et al., 2011).
In addition to ideal therapeutic target, safe and efficient
delivery carrier is another crucial factor for successful gene
therapy. Naked siRNAs is easy to be degraded by RNase, leading
to its short half-life. More importantly, because of it negatively
charged nature, free siRNA is unable to penetrate the cell
membrane (Whitehead et al., 2009). To address this issue, a
variety of carriers have been extensively utilized to facilitate the
delivery of siRNA into cytoplasm (Shi et al., 2014; Dim et al.,
2015; Li et al., 2015; Fitzgerald et al., 2016; Warashina et al.,
2016). Among them, fluorescent quantum dots (QDs) have been
investigated as potential carriers for the loading of genemolecules
owing to their stable chemical properties and large surface area
(Jung et al., 2010; Zhao et al., 2013; Wang et al., 2015). What’s
more important, QDs have unique optical features such as high
resistance to photobleaching, size-tunable fluorescent peaks and
a broad excitation profile with narrow emission spectra (Bruchez
et al., 1998). These exceptional optical properties make them
useful for real-time monitoring of the siRNA delivery process
in situ.
In this study, we developed cadmium sulphoselenide/Zinc
sulfide quantum dots (CdSSe/ZnS QDs)-based nanocarriers for
in vitro gene delivery. These CdSSe/ZnS QDs are conjugated
with Polyethyleneimine (PEI) to form stable nanoplex (QD-PEI)
with enhancing zeta potential and subsequently used for siRNA
loading through electrostatic interaction. For genetic therapy of
glioblastoma, we designed siRNA sequences specifically targeting
TERT gene. In our experiments, two different glioblastoma cell
lines (U87 and U251) were used for comparison studies. We
found that the delivery of siRNA by QD-PEI nanoplex was
effective and the gene expression of TERT was successfully
suppressed. We also observed the down-regulation of TERT gene
had inhibited the proliferation of the glioblastoma cells and we
envisioned that such engineered approach might serve as a new
and effective way for combating glioblastoma gene therapy.
MATERIALS AND METHODS
Preparation and Characterization of QDs
CdSSe/ZnS QDs were purchased from Najingtech Company and
it is terminated with COOH surface groups by coating with a
polymer layer. The fluorescence spectra of CdSSe/ZnS QDs were
determined by a spectrophotometer (F-4600, Hitachi, Japan). The
hydrodynamic size distribution of the QDs was obtained using
a dynamic light scattering (DLS) machine (Zetasizer Nano ZS,
Malvern, UK). The morphology images of CdSSe/ZnS QDs were
obtained with a transmission electronmicroscope (TEM) (Tecnai
G2 F20 S-TWIN, FEI, USA) operating at an accelerating voltage
of 200 kV at room temperature.
Cell Culture
The human neuroglioma cells U87 and U251 were obtained
fromAmerican Type Culture Collection (ATCC) andmaintained
in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) and
RMPI 1640 medium respectively. The culture mediums were
supplemented with 10% fetal bovine serum (FBS) (Gibco),
penicillin (100U, Gibco) and streptomycin (100U, Gibco). Cells
were kept at 37◦C in a humidified incubator with 5% CO2.
Preparation of QD-PEI Particles
Branched PEI reagent with 25 KDa molecular weight (Sigma,
US) was used to modify the surface of the QDs. Briefly, 50
µL of QDs solution (1 mg/mL) was mixed with 250 µL of
PEI solution at different concentrations (0.05, 0.1, 0.25, and 0.5
mg/mL, in deionized water), followed by short sonication and
vortexing for 20min. Then the QD-PEI particles were collected
by centrifugation at 14,000 rpm for 10min. The resultingQD-PEI
particles were dispersed in 200 µL of DEPC-treated water while
the aggregates were removed by spinning down at 2,000 rpm for
1min.
Transfection
Scramble siRNA, TERT siRNA, and TERT siRNAFAM were
purchased from Genepharma Company, China. The siRNAs
with FAM probe were used for laser scanning confocal imaging
analysis and flow cytometry assay. The day before transfection,
cells were planted onto 6-well plates in medium without
antibiotics to give 30–50% density. For siRNA loading, QD-PEI
particle (100 µg/mL, 40 µL) was mixed with siRNAs (10 µM, 10
µL) with gentle vortexing, and the mixture was left undisturbed
for 30 min. Before transfection, the culture medium was replaced
by fresh medium without FBS, and the above mentioned QD-
PEI-siRNA mixture was then added to the medium with a final
volume of 2mL (2 µg/mL QD-PEI). Scramble siRNA with non-
targeted siRNA sequences was used as a negative control at
the same dosage. In a parallel experiment, Lipofectamine2000
(Invitrogen), a frequently reported commercial transfection
reagent was used as positive control. The transfection efficiency
was observed at 4 h post-transfection, and the gene and protein
expression was determined at 48 h post-transfection.
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Laser Scanning Confocal Imaging
Four hours after transfection, the in vitro confocal images were
obtained using a laser scanning confocal microscope (LSCM)
(TCS SP5, Leica, DEU). The FAM signals from siRNAs were
utilized to monitor the siRNAs. Before imaging, the cell medium
was removed and cells were washed with phosphate-buffered
saline (PBS) twice, fixed with formaldehyde (4%) for 10min.
Then the formaldehyde solution was removed and the nuclei
were stained with DAPI (Sigma) for 5min. To image the cells,
filter sets for DAPI (excitation: 405 nm; emission: 450/50 nm) and
FAM (excitation: 488 nm; emission: 525/50 nm) were applied,
respectively.
Flow Cytometry
For the flow cytometry assays, cells were washed twice with PBS
solution and harvested by trypsin (Gibco). The FAM signals from
siRNAs were utilized to determine the transfection efficiency
quantitatively. After trypsinization, the cells were resuspended
in 500 µL PBS solutions and analyzed immediately by a flow
cytometry machine (FACSAria II, BD, USA).
Quantitative Gene Expression Analysis
Forty-eight hours after transfection, total RNA of U87 and
U251 cells was extracted using TRIzol reagent (Invitrogen)
and quantitated by a spectrophotometer (Epoch, BioTek, USA).
Total RNA (1 µg) was reverse transcribed to cDNA using
one-step reverse transcriptase kit (TransGen) according to the
manufacturer’s instructions. Real-time polymerase chain reaction
(TransGen) was then performed by a PCR machine (CFX96,
Bio-Rad, USA). The TERT gene expression level was normalized
to the expression of a commonly used housekeeping gene,
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers
used were as follows:
TERT: 5′-AGAGTGCCTTGACGATACAGC-3′ (sense), 5′-A
CAAAGAAAGCCCTCCCCAGT-3′ (antisense); GAPDH: 5′-A
CCACAGTCCATGCCATCAC-3′ (sense), GAPDH5′-TCCACC
ACCCTGTTGCTGTA-3′ (antisense).
Western Blot Analysis
Forty-eight hours after transfection, total proteins of U87 and
U251 cells were extracted using M-PER Mammalian Protein
Extraction Reagent (Thermo) and quantitated by BCA Reagent
(Tiangen). Proteins (16 µg) were electrophoresed through 8%
(w/v) polyacrylamide, 0.5% (w/v) SDS gels. Proteins were
transferred to nitrocellulose membrane (Millipore), followed
by blocking with 5% (w/v) non-fat milk in TBST buffer
for 1 h at room temperature, incubatingwith TERT and β-
tubulin antibody (1:1,000; GeneTex) overnight at 4◦C. Primary
antibody was detected using horseradish peroxidase-conjugated
goat anti-rabbit IgG-HRP (1:1,000; NeoBioscience). Blots were
developed with clarity western ECL substrate kit (BioRad, USA)
and imaged by chemiluminescence imaging system (Qinxiang
science instruments, China). The relative protein expression
level of TERT was normalized to the expression of β-tubulin.
The relative expression level was expressed as a percentage,
assigning the relative expression level of TERT in Blank group
as 100%.
Cell Viability
Cell viability was measured by the MTS (Promega) assay. Cells
were seeded in 96-well plates (5 × 103 cells/well) and incubated
with different concentrations of QD-PEI solutions for 24 or 48 h.
MTS solution in PBS buffer was added into the cells and the cells
were incubated for 4 h at 37◦Cwith 5%CO2. The cells were gently
shaked for 5min and absorbance wasmeasured with amicroplate
reader (Epoch, Bio-Tek, USA) at a wavelength of 490 nm. The
cell viability was calculated by normalizing the absorbance of the
QDs-treated well against that of the control well. The cell viability
was expressed as a percentage, assigning the viability of control
cells as 100%.
Statistical Analysis
All data were presented as mean± SD. The results were analyzed
via one-way ANOVA with a post-hoc Dunnett test to determine
statistical significance. All statistical calculations were performed
with the SPSS 11.0 software package. A p value less than 0.05 was
regarded as statistically significant difference.
RESULTS
Figure 1A shows the absorption and photoluminescence spectra
of the dispersion of carboxyl-terminated CdSSe/ZnS QDs
in water. The QDs exhibit an absorption peak at 590 nm
and an emission peak at 630 nm. Due to the presence of
carboxylic groups on the shells, the CdSSe/ZnS QDs were
negatively charged with zeta potential value of −45.6 mV.
The TEM image of the CdSSe/ZnS QDs showed that the
nanocrystals are highly monodispersed (Figure 1B) in their
size distribution. Figure 1C shows the hydrodynamic size
distribution of the QDs characterized by DLS. The QDs have
a narrow size distribution with a hydrodynamic diameter of
12.97± 4.62 nm.
For siRNA loading, PEI was used to modify the surface of
the QDs. Figure 2A shows the scheme of the QD–PEI-siRNA
nanoplexes. By changing the PEI concentration, the QD-PEI
clusters can be prepared with different hydrodynamic sizes
(87.8∼209.4 nm), and the surface zeta potential can also be
tailored ranging from +6.44 to +36.10 mV (Figures 2B,C).
The high zeta potential is crucial for siRNA loading since
the siRNAs are negatively charged by nature. The negatively
charged siRNAs can be conjugated to the QD-PEI nanoparticles
through electrostatic interaction. Finally, PEI solution of 0.5
mg/mL was used to modify the QDs, and QD-PEI solution
at final concentration of 2 µg/mL was utilized for siRNAs
transfection.
To construct an efficient gene nanocarrier, the prepared
nanoparticles should be biocompatible. In order to determine
the safe dosage range of the QD-PEI formulation, in vitro cell
viability studies were carried out by using MTS assay. The
U251 and U87 cells were treated with various doses of QD-
PEI formulation for 24 or 48 h. Figure 3 shows that over 90%
cell viability was maintained when the applied doses of QD-
PEI formulation ranged from 0.625 to 20 µg/mL (within 24 and
48 h). According to our results, the QD-PEI formulation should
have limited cytotoxicity effects on the cells if the concentration
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FIGURE 1 | The characterization of the CdSSe/ZnS QDs. (A) Absorption and photoluminescent spectra of the CdSSe/ZnS QDs. (B) TEM image of the
CdSSe/ZnS QDs. (C) DLS measurement of the CdSSe/ZnS QDs in deionized water.
FIGURE 2 | The characterization of the QD–PEI nanoparticle. (A) Scheme of the QD–PEI-siRNA nanoplexes. (B) Hydrodynamic size and (C) surface zeta
potential of the QD-PEI clusters prepared using different PEI concentrations. Values are means ± SD, n = 3.
of the nanoplex is below 20 µg/mL (10 times of transfection
concentration).
The QD-PEI particles were then served as nanocarriers to
deliver siRNAs which target human TERT gene in human
neuroglioma cell lines, U87 and U251. It is worth mentioning
that TERT is the catalytic protein subunit of telomerase, and
it is important for maintaining the activity of telomerase in
cancer cells. Figure 4 shows the confocal images of tumor cells of
4 h post-transfection with different nanoplexes. The fluorescent
signal from TERT siRNAs was detectable in cells treated with
QD-PEI-siRNA formulation, where the TERT siRNAs were
labeled with fluorescence FAM. Similar results were also observed
in the positive control group where the commercially available
transfection reagent Lipofectamin2000 was used to deliver the
siRNAs. The results demonstrate that the TERT siRNAs were
successfully delivered into the cells by functionalizing them
to QD-PEI formulation. In contrast, no fluorescence signal is
detected in the cells treated with naked siRNAs, suggesting that
the free siRNAs are unable to penetrate the cell membrane in the
absence of delivery nanovectors.
In order to further quantitatively evaluate the transfection
efficiency of siRNAs by QD-PEI, flow cytometry assay was
performed. Figure 5 shows the representative images of the
FAM fluorescence intensity in U251 cells treated with different
nanoplexes for 4 h. Consistent with the confocal imaging
analysis, the result shows that almost no fluorescence signal
is detected for the cells treated with naked TERT siRNAFAM
(6.78 ± 7.85%) and QD-PEI alone (0.27 ± 0.24%). As a
comparison, cells treated with Lipo-siRNAFAM and QD-PEI-
siRNAFAM showed strong fluorescence signals, suggesting the
abundant accumulation of siRNAFAM in the tumor cells. The
fraction of the tumor cells with positive FAM fluorescence signals
for the cells treated with QD-PEI-siRNAFAM is estimated to
be 80%. These results demonstrated that the QD-PEI nanoplex
formulation can be utilized as an efficient siRNA delivery
nanovector.
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FIGURE 3 | Cytotoxicity tests of QD-PEI formulation by MTS assays. (A) U251 cells and (B) U87 cells were treated with different concentrations of QD-PEI
formulation for 24 or 48 h. Values are means ± SD, n = 5.
To confirm that we had a successful knocking down process
in vitro, the mRNA and protein expression level of the targeted
TERT gene was determined by real-time PCR and Western
blot analysis. Figures 6A,B shows the quantitative expression of
TERT mRNA in U251 and U87 cells transfected with different
formulations for 48 h. The results demonstrate that the cells
treated with TERT siRNA, QD-PEI, QD-PEI-Scramble siRNA
and Lipo-Scramble siRNA exhibited minimal suppressions upon
comparing to the cells without any treatment. In contrast,
the expression level of TERT mRNA in cells transfected with
QD-PEI-TERT siRNA nanoplex was found to be significantly
suppressed (p < 0.01). The mRNA expression level of QD-PEI-
TERT siRNA was 43.28 ± 9.66% for U251 cells and 49.99 ±
10.23% for U87 cells. No difference was observed in the mRNA
expression between cells treated with QD-PEI-TERT siRNA and
cells treated with Lipo-TERT siRNA (p > 0.05). Consistent
result for TERT protein expression was obtained by Western
blot analysis (Figures 6C,D). The TERT protein expression level
of QD-PEI-TERT siRNA was determined to be 50.69 ± 7.59%
for U251 cells and 51.58 ± 7.88% for U87 cells. These results
suggest that the formulation presented here is effective for gene
silencing and can be served as a good platform for gene therapy
applications.
In addition to the gene silencing efficiency, to evaluate the
targeted gene therapeutic effects of the TERT siRNAs delivered
by QD-PEI formulation, the viability of the cells with 48-h
treatment were examined by MTS assays. Both U251 and U87
cells were treated with different nanoformulations for 48 h and
their corresponding cell viabilities were evaluated. As shown
in Figure 7, no significant difference was observed in the cell
proliferation ability between the Blank, TERT siRNA, QD-
PEI, and QD-PEI-Scramble siRNA groups. On the contrary, an
evident decrease in the cell viabilities was observed for the cells
treated with QD-PEI-TERT siRNA formulation upon comparing
to the cells without any treatment (p < 0.05). No difference was
observed in the cell viability between cells treated with QD-PEI-
TERT siRNA and cells treated with Lipo-TERT siRNA (p> 0.05).
This indicates that TERT siRNAs delivered by QD-PEI particle is
an efficient and promising strategy to suppress the proliferation
of both the U251 and U87 human neuroglioma cells.
DISCUSSION
The aggressiveness of glioblastoma has made it the most deadly
CNS tumor (Adamson et al., 2009). The siRNAs-based RNAi
technology has brought potential promises for patients to fight
against this deadly disease by gene therapy approach (Gan et al.,
2016). Great efforts have been made by the medicine research
community to seek effective gene targets for treating glioblastoma
and several strategies have been proposed and identified (Zorzan
et al., 2015). In this study, anti-tumor therapeutics targeting
TERT was employed as a unique therapy strategy due to the high
prevalence of telomerase in most of the tumor cells (Ruden and
Puri, 2013).
Besides therapeutics target, an ideal delivery vehicle with high
gene knocking down efficiency is still in urgent need for RNAi-
based gene therapy since naked siRNAs are extremely unstable
and negatively charged (Whitehead et al., 2009). Previously,
viral vectors have been demonstrated as promising gene delivery
carriers owing to their high transfection efficiency (Couto and
High, 2010). However, along with the rise of concern on
biosafety issues and immune response problems, the application
of viral vectors was severely impeded (Chira et al., 2015). As
a result, non-viral vehicles for siRNA delivery have emerged as
an alternative method and it has been investigated by many
research groups around the globe (De Laporte et al., 2006; Chira
et al., 2015). Compared with viral vectors, non-viral vectors have
several advantages such as ease of design and synthesis, flexible
surfacemodifications, tremendous potential for optimization and
enhanced biosafety (Chen and Huang, 2008; Wong et al., 2012;
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FIGURE 4 | Laser confocal images of U251 cells treated with different nanoformulations. (I) Blank, (II) free siRNAFAM, (III) QD-PEI, (IV) QD-PEI-siRNAFAM, and
(V) Lipo-siRNAFAM for 4 h. Cell nucleus is stained with DAPI (in blue), signals from QD are assigned in red and signals from FAM are assigned in green.
Lin et al., 2013). More importantly, these non-viral vectors are
potential candidates to be translated to clinical usage (Merkel
et al., 2014).
Previously, several studies have already shown the application
prospects of QDs in gene transfer and therapy (Chen et al.,
2005; Jung et al., 2010; Li et al., 2011, 2012; Zhao et al.,
2013). QDs-based methods include the advantages of real-
time imaging and monitoring the intracellular trafficking of
small molecules within the cells. Chen et al. demonstrated a
method of monitoring and improving siRNA delivery using
water-dispersible and mercaptoacetic acid-coated (MAA) QDs
where their surface was modified with polyethylene glycol (PEG)
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FIGURE 5 | Transfection efficiency of U251 cells determined by flow cytometry analysis. (A) Representative pictures, where cells were treated with (I) Blank,
(II) free siRNA, (III) QD-PEI, (IV) Lipo-siRNA, and (V) QD-PEI-siRNA. (B) Percentage of cells transfected after 4-h treatment, evaluated from experiments shown in (A).
Values are means ± SD, n = 4.
(Chen et al., 2005). Li et al. reported the delivery of QD-siRNA
nanoplexes into SK-N-SH cell line for BACE1 gene silencing
and effective monitoring the spatiotemporal distribution and
dynamics of QDs by real-time intracellular imaging (Li et al.,
2012). In this study, carboxyl–terminated CdSSe/ZnS QDs were
designed for the delivery of siRNAs into the glioblastoma cells.
Because of the carboxylic groups terminated on their surface, the
CdSSe/ZnS QDs have a negatively charged surface and the zeta
potential is determined to be −45.6 mV. To increase the value
of zeta potential, the QDs were further functionalized with PEI
which was needed for gene transfection application (Lu et al.,
2015; Chen et al., 2016). Owing to their large density of positively
charged amino groups, PEI has a strong ability for DNA binding
and cell adhesion. After functionalizing the QDs with PEI, the
zeta potential of QD-PEI nanoformulation was increased. This
is desirable for gene delivery because it enhances the efficiency
of siRNA loading through the electrostatic interaction. It is
worth mentioning that higher charge density will generally
provide higher loading efficiency of the oppositely charged siRNA
molecules, but excess charge on the QDs surface will result in
the decrease of the siRNAs release owing to the strong binding
interaction between the QDs and siRNA molecules (Wang et al.,
2015). Wang et al. suggested that a zeta potential value ranged
from +20 to +40 mV is optimal for the formation of nanoplex
and allowing them to be effectively delivering siRNAs to the cells
(Wang et al., 2015). Consistently, in this study, the zeta potential
of nanoplex of CdSSe/ZnS QDs is estimated to be+36 mV, which
is suitable for the siRNA delivery.
After the transfection, the gene transfection efficiency, the
gene expression level, as well as the cell viability were determined.
We found that the delivery of siRNAs by QD-PEI nanocarrier
was highly effective and the proliferation of tumor cells
was successfully suppressed, suggesting that QD-PEI-siRNA
complexes were able to escape from the endosomes and releasing
the siRNAs into the cytoplasm. Also, efficient gene silencing
and cell proliferation inhibition was achieved by TERT mRNA
targeting, which thereby inducing the specific siRNA-induced
gene silencing. To date, very little is known for the intracellular
events of QDs as siRNA carriers. Based on current findings,
one can deduce that PEI molecule has high density of amine
groups and they are able to exert proton sponge effect whereby
promoting the inhibition of acidification of endosomal pH.
This will leads to the net influx of chloride ions within the
compartment, leading to the osmotic swelling and rupture of
endosomal membrane, a phenomenon often called the “proton
sponge effect” (Ramamoorth and Narvekar, 2015).
To be an efficient carrier, the applied nanoparticles must be
biocompatible. The unique optical property of QDs makes them
desirable for imaging and targeted delivery, but the presence
of cadmium element in the QDs also creates great concern in
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FIGURE 6 | The mRNA and protein expression levels of the TERT gene. (A,B) TERT mRNA relative expression levels in (A) U251 cells and (B) U87 cells
determined by real-time PCR. (C,D) Representative images of TERT protein expression and relative expression levels in (C) U251 cells and (D) U87 cells determined
by Western Blot analysis. Lane1-8 refer to Blank, TERT siRNA, QD-PEI, Protein marker, QD-PEI-TERT-siRNA, Lipo-TERT-siRNA, QD-PEI-Scramble siRNA, Lipo-
Scramble-siRNA. Values are means ± SD, n = 3. Values are means ± SD, n = 5. **p < 0.01 vs. Blank.
the medical field since cadmium can cause strong toxicological
impact to the body. Some in vitro studies have demonstrated that
QDs are harmful to the cells if high doses of QDs are exposed
and in general many of these QDs are not well passivated with
coatings. Sung et al. revealed that long-term exposure to CdTe
QDs to the cells can cause Cd2+ release and generating reactive
oxygen species (ROS) which subsequently led to functional
impairments to MCF-7 cell line (Cho et al., 2007). Similarly,
Wang et al. reported that exposure to CdSe QDs resulted in
cultured intestinal cell detachment and death (Wang et al.,
2008). In practice, the cytotoxicity of QDs is based on several
factors such as their inherent chemical composition, surface
modification and charge (Hardman, 2006). If appropriate shell
protection and surface coating are applied to the nanocrystals
surface, the QDs can be made with low toxicity. Here, the
CdSSe/ZnSQDs used are coatedmultilayer-shell, which increases
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FIGURE 7 | Cell viabilites of cells treated with different nanoformulations, (A) U251 cells and (B) U87 cells. Values are means ± SD, n = 5. *p < 0.05 vs. Blank.
the stability of QDs and decreases the cytotoxicity. After 48 h of
treating the U87 and U251 cells with PEI modified CdSSe/ZnS
QDs at 10 times of the transfected dose, no cytotoxicity sign was
observed. These results indicated that QDs presented here is safe
for transfection and can be applied for QDs-based gene delivery
application.
In summary, we designed and prepared QD-PEI
nanoformulation for efficient gene delivery and silencing, and
the nanoplex developed here will serve as a promising candidate
for gene therapy of central nervous system tumors. Although,
the complete suppression of the cancer cell proliferation is still
challenging, the development of the QD-PEI formulation in this
study will certainly laid an important foundation in providing
valuable information to guide future studies on gene therapy
of cancers. With these inspiring results, we believe that further
improvement in the QDs-based siRNA delivery strategy will
allow one to achieve better application prospects in cancer gene
therapy.
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